Top Analyst Stocks
Up to the top 50 stocks backed by Wall Street’s most accurate analysts. A stock only makes this list when at least one analyst with a measured success rate of 70% or better holds a live price target on it, and the ranking combines how many of those analysts cover it, how accurate they have been, and the upside to the average of their targets. Informational, not investment advice.
Right now 58 stocks clear that bar, out of 88 carrying a live target from at least one of the 27 analysts above 70% on our leaderboard. The list grows as more of their calls season into a measured track record.
| # | Symbol | Company | Rating | Analysts | Avg target | Upside | Market cap |
|---|---|---|---|---|---|---|---|
| 1 | STOK | Stoke Therapeutics, Inc. | Buy | 11 | $51.00 | +100.0% | $1.65B |
| 2 | MOD | MODINE MANUFACTURING CO | Buy | 22 | $345.00 | +97.1% | $9.30B |
| 3 | FTAI | FTAI Aviation Ltd. | Buy | 16 | $321.25 | +92.3% | $17.16B |
| 4 | PHVS | Pharvaris N.V. | Buy | 22 | $60.75 | +90.4% | $2.24B |
| 5 | TNGX | Tango Therapeutics, Inc. | Buy | 22 | $45.91 | +88.9% | $4.10B |
| 6 | FN | Fabrinet | Buy | 10 | $769.50 | +87.7% | $14.69B |
| 7 | FUN | Six Flags Entertainment Corporation/NEW | Buy | 21 | $21.57 | +86.9% | $1.18B |
| 8 | XENE | Xenon Pharmaceuticals Inc. | Buy | 24 | $68.63 | +86.9% | $3.56B |
| 9 | TNDM | TANDEM DIABETES CARE INC | Buy | 26 | $30.17 | +83.7% | $1.14B |
| 10 | CPNG | Coupang, Inc. | Buy | 15 | $25.25 | +83.6% | $24.72B |
| 11 | RARE | Ultragenyx Pharmaceutical Inc. | Buy | 42 | $26.25 | +82.2% | $1.42B |
| 12 | MAIR | Madison Air Solutions Corp | Buy | 11 | $44.63 | +78.7% | $12.53B |
| 13 | RSI | Rush Street Interactive, Inc. | Buy | 21 | $34.88 | +78.4% | $4.78B |
| 14 | ORCL | ORACLE CORP | Buy | 78 | $236.52 | +78.4% | $400.95B |
| 15 | BTDR | Bitdeer Technologies Group | Buy | 18 | $19.60 | +77.7% | $3.00B |
| 16 | VRDN | Viridian Therapeutics, Inc. DE | Buy | 25 | $36.43 | +77.1% | $2.33B |
| 17 | ETOR | eToro Group Ltd. | Buy | 23 | $45.63 | +76.7% | $2.05B |
| 18 | DFTX | Definium Therapeutics, Inc. | Buy | 28 | $67.45 | +75.6% | $5.16B |
| 19 | FLUT | Flutter Entertainment plc | Buy | 58 | $133.13 | +73.7% | $13.30B |
| 20 | KTB | Kontoor Brands, Inc. | Buy | 16 | $112.50 | +73.3% | $3.55B |
| 21 | BCAX | Bicara Therapeutics Inc. | Buy | 12 | $32.57 | +73.2% | $1.24B |
| 22 | HUT | Hut 8 Corp. | Buy | 30 | $160.54 | +73.2% | $11.43B |
| 23 | PTRN | Pattern Group Inc. | Buy | 22 | $29.00 | +72.9% | $3.34B |
| 24 | PLNT | Planet Fitness, Inc. | Buy | 36 | $69.18 | +70.8% | $3.07B |
| 25 | BRBR | BELLRING BRANDS, INC. | Buy | 31 | $13.20 | +70.5% | $899.99M |
| 26 | CYTK | CYTOKINETICS INC | Buy | 31 | $112.50 | +70.0% | $9.20B |
| 27 | EYE | National Vision Holdings, Inc. | Buy | 13 | $27.20 | +68.7% | $1.27B |
| 28 | MAMA | Mama's Creations, Inc. | Buy | 12 | $22.00 | +67.3% | $619.99M |
| 29 | PVLA | PALVELLA THERAPEUTICS, INC. | Buy | 28 | $233.80 | +67.2% | $2.01B |
| 30 | INSM | INSMED Inc | Buy | 55 | $196.33 | +66.8% | $25.70B |
| 31 | BBIO | BridgeBio Pharma, Inc. | Buy | 37 | $110.09 | +65.3% | $13.02B |
| 32 | ELVN | Enliven Therapeutics, Inc. | Buy | 12 | $76.00 | +65.2% | $3.37B |
| 33 | RRX | REGAL REXNORD CORP | Buy | 16 | $258.20 | +65.0% | $10.42B |
| 34 | CLSK | CLEANSPARK, INC. | Buy | 17 | $22.00 | +64.9% | $3.43B |
| 35 | IRON | Disc Medicine, Inc. | Buy | 17 | $106.00 | +63.3% | $2.49B |
| 36 | COGT | Cogent Biosciences, Inc. | Buy | 13 | $51.75 | +62.4% | $5.53B |
| 37 | PENN | PENN Entertainment, Inc. | Buy | 21 | $24.60 | +61.4% | $2.04B |
| 38 | PTCT | PTC THERAPEUTICS, INC. | Buy | 22 | $106.00 | +60.7% | $5.50B |
| 39 | GENI | Genius Sports Ltd | Buy | 27 | $9.85 | +60.2% | $1.65B |
| 40 | SW | Smurfit Westrock plc | Buy | 24 | $71.50 | +58.6% | $23.64B |
| 41 | DKNG | DraftKings Inc. | Buy | 67 | $33.56 | +58.6% | $10.50B |
| 42 | VST | Vistra Corp. | Buy | 30 | $217.45 | +57.5% | $46.32B |
| 43 | ANAB | ANAPTYSBIO, INC | Buy | 23 | $79.17 | +55.9% | $1.52B |
| 44 | BMRN | BIOMARIN PHARMACEUTICAL INC | Buy | 44 | $90.88 | +52.8% | $11.51B |
| 45 | MNPR | Monopar Therapeutics | Buy | 16 | $126.00 | +50.5% | $561.94M |
| 46 | AVAV | AeroVironment Inc | Buy | 38 | $220.33 | +49.6% | $7.48B |
| 47 | RLAY | Relay Therapeutics, Inc. | Buy | 15 | $26.25 | +48.4% | $3.88B |
| 48 | CECO | CECO ENVIRONMENTAL CORP | Buy | 12 | $106.80 | +47.8% | $4.23B |
| 49 | PURR | Hyperliquid Strategies Inc | Buy | 10 | $19.80 | +40.5% | $1.90B |
| 50 | OWL | BLUE OWL CAPITAL INC. | Buy | 27 | $11.18 | +22.2% | $14.34B |
Every analyst with a price target on file over the trailing year, not a starred subset. A stock appears when at least 10 analysts cover it, the consensus is buy-rated, and the average target is above the current price; rows are ranked by that room. Informational, not investment advice.
Success rates are measured from each analyst’s own past price targets — the share of their seasoned calls (30 days or older) that moved in the direction the target implied — so only analysts with a real track record can put a stock on this list. Targets older than a year are treated as history, not live coverage. Upside is the move from the current price to the covering analysts’ average target. Informational, not investment advice.